Journey Medical (DERM) announced that a data analysis from two Phase 3 multicenter clinical trials, evaluating Emrosi for the treatment of moderate-to-severe papulopustular rosacea in adults will ...

Emrosi is the lowest FDA-approved oral dose of minocycline that does not require weight-based dosing adjustments, according to the company’s press release. The prescription medication is currently ...

“These compelling Phase 3 results reinforce the potential of Emrosi to become a new standard of care for patients with rosacea. Emrosi is the lowest oral dose of minocycline approved by the FDA ...

The analysis determined that differences in body weight did not affect the efficacy of Emrosi in the two Phase 3 trials, which supported its November 2024 FDA approval.

Emrosi is a FDA-approved treatment for inflammatory lesions of rosacea, containing 40 mg of Minocycline Hydrochloride in modified-release capsules. When did the national TV segment on Emrosi air?

The feature included insights from Pura Dermatology’s Saurabh Lodha, MD, FAAD, who discussed Emrosi’s unique formulation and its significance in the treatment landscape for rosacea. Approved by the ...